Results 51 to 60 of about 6,111 (249)

Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris. [PDF]

, 2017
Treatment of pityriasis rubra pilaris (PRP) is solely based on its resemblance to psoriasis rather than any knowledge of its pathomechanism. Insight into pathogenic mediators of inflammation is essential for targeted and valid treatment options that ...
Conrad, C., Demaria, O., Feldmeyer, L., Gilliet, M., Hohl, D., Laffitte, E., Mennella, A., Mylonas, A., Yawalkar, N.   +8 more
core   +2 more sources

Risankizumab for the treatment of pityriasis rubra pilaris postanaplastic large cell lymphoma. [PDF]

JAAD Case Rep
Koroneos G, Nicolopoulos J, Dolianitis C.   +2 more
europepmc   +2 more sources

Pityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab. [PDF]

An Bras Dermatol
Vieira Granja B, Amoedo P, Gomes NP, Costa C, Azevedo F, Magina S.   +5 more
europepmc   +2 more sources

Ustekinumab-Induced Fatal Acute Heart Failure in a Young Female: A Case Report

Methodist DeBakey Cardiovascular Journal, 2022
Data regarding short- and long-term cardiovascular complications of biological agents is lacking. Herein, the authors reported a case of abrupt onset of acute heart failure induced by ustekinumab treatment for resistant pityriasis rubra pilaris in a ...
Mahmoud Abdelnabi, Saif ElNawaa, Juthipong Benjanuwattra, Mohamed Elmassry, Nandini Nair   +4 more
doaj   +1 more source

Learning differential diagnosis of erythemato-squamous diseases using voting feature intervals [PDF]

, 1998
Cataloged from PDF version of article.A new classification algorithm, called VFI5 (for Voting Feature Intervals), is developed and applied to problem of differential diagnosis of erythemato-squamous diseases.
Demiroz, G., Guvenir, H. A., Ilter, N.
core   +1 more source

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab

Case Reports in Dermatology, 2018
Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause and often confounded with psoriasis. It is characterised by hyperkeratotic follicular papules, scaly erythematous plaques, palmoplantar keratoderma, and a progression to ...
Kathrin Hanfstingl, Agnes Pekar-Lukacs, Reinhard Motz, Emmanuella Guenova, Wolfram Hoetzenecker   +4 more
doaj   +1 more source

Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab. [PDF]

JAAD Case Rep, 2023
Saad M, Bose R.
europepmc   +2 more sources

CARD14 gain-of-function mutation alone is sufficient to drive IL-23/IL-17-mediated psoriasiform skin inflammation in vivo [PDF]

, 2018
Rare autosomal dominant mutations in the gene encoding the keratinocyte signaling molecule, Caspase Recruitment Domain-Containing Protein 14 (CARD14), have been associated with an increased susceptibility to psoriasis but the physiological impact of ...
Cheng, Phil, Contassot, Emmanuel, French, Lars E, Kiefer, Betina, Meier, Barbara, Mellett, Mark, Mohanan, Deepa, Nobbe, Stephan, Ospelt, Caroline, Satoh, Takashi K, Schairer, Rebekka, Thome, Margot   +11 more
core   +1 more source

The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside

Frontiers in Immunology, 2020
Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells.
Taoming Liu, Sheng Li, Shuni Ying, Shunli Tang, Yuwei Ding, Yali Li, Jianjun Qiao, Hong Fang   +7 more
doaj   +1 more source

Morbus‐Grover‐artige Muster in der Frühphase der Pityriasis rubra pilaris [PDF]

J Dtsch Dermatol Ges
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 2, Page 231-233, February 2025.
Hoffmann J, Durani B, Hartschuh W.
europepmc   +2 more sources